The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Contact Press team

Press Release

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL.

A close up of a cell in the air.

Press Release

event

NeuroNova

Supernova

RTNova

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET.

January 29, 2025

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its ending cash balance at December 31, 2024 was approximately $9.6 million. Due to Calidi’s bolstered cash balance and success in recent fundraising, including proceeds resulting from its At-The-Market Offering Agreement (“ATM”), Calidi terminated its Standby Equity Purchase Agreement (“SEPA”) with YA II PN, Ltd., an affiliate of Yorkville Advisors, effective January 23, 2025.

January 28, 2025

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapy, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, IL.

January 13, 2025

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.

January 10, 2025

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share.

January 10, 2025

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

January 8, 2025

Press Release

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL.

April 28, 2025

Press Release

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company’s common stock on April 22, 2025, the date of grant (the “Stock Options”).

April 25, 2025

Press Release

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.

April 23, 2025

Press Release

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET.

April 22, 2025

Press Release

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma.

April 17, 2025

Press Release

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor.

April 10, 2025

Publication

event

NeuroNova (NNV)

NeuroNova (NNV)

NeuroNova

Supernova

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018

Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019

Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.